iZafe Group AB ("iZafe Group") is pleased to announce the successful implementation of their medication robot, Dosell, in Spain. The company has now completed all necessary technical integrations and adjustments required to launch Dosell in the Spanish market after a series of successful integrations. These adaptations encompassed both technical refinements to the Dosell unit itself and the platform, as well as extensive developments and adjustments by our collaboration partner.

As a significant step forward, iZafe Group has now delivered the first 30 Dosell units to Ti-Medi to commence practical testing of the customer journey over the nexts months. This phase of the pilot program will contribute to ensuring a seamless launch and customer experience. Upon successful completion of the testing phase, commercial sales will commence after the turn of the year, in accordance with the previously communicated plan.
 
"We are thrilled to announce the successful delivery of our cutting-edge pharmaceutical robot, Dosell, to the thriving market of Spain. This marks a significant milestone in our mission to helping patients taking the right medication at the right time in yet another country. We are committed to providing innovative solutions that empower healthcare professionals and improve patient care. This achievement is a testament to the hard work and dedication of our team, and we look forward to making a positive impact on the healthcare landscape in Spain and beyond." Says Anders Segerström, CEO of iZafe Group AB
 
"We're excited to announce a big change in our business model as we start focusing on serving individual consumers (B2C). This shift is a major milestone for us, and we know there's a lot of work to do. We're staying dedicated to working closely with our trusted pharmacy partners to make sure our pilot program gets the attention and resources it needs. We're confident that by leveraging our current partnerships and industry knowledge, this initiative will be a valuable learning experience. We're teaming up with iZafe to bring innovative solutions to the B2C market in the MDS industry." Rafa Tibau, CIO of Ti-Medi.

iZafe Group's CEO, Anders Segerström, has today acquired an additional 208,333 B-shares in the company. The transaction was completed at a total value of 50,000 SEK, equivalent to 0.24 SEK per share. With this latest purchase, Anders Segerström now holds a total of 1,598,773 B-shares in iZafe Group.

"It is with pleasure and belief that I increase my ownership stake in iZafe Group. This decision reflects my full confidence in our dedicated team and our future potential. Today, we stand on a strong foundation to collectively continue working hard towards creating a successful future for our shareholders, the company, individuals who require multiple medications, society, and healthcare." says Anders Segerström, CEO iZafe Group AB.

iZafe group AB (publ.) is proud to present an exciting new development in the company's identity and expression. With the goal of further strengthening its presence on the international scene, the company is today launching an updated logo and design, in parallel with the launch of a new website that is in both Swedish and English.

iZafe's current logo and color language were developed when the company focused on both safety and health. iZafe implements this change to better reflect the company's current vision and direction and make it easier for owners and other stakeholders to get a correct and comprehensive picture of where the company stands and is headed.
The new design captures the company's dedication to developing digital products to ensure the right medication at the right time, while standing as a symbol of precision and care for each individual patient.
 
At the center of the new logo is a subtle pill shape, surrounded by rings reminiscent of fingerprints. This design highlights the uniqueness of the individual and the company's focus on patients. The clean and elegant lines radiate efficiency and streamlined operations, demonstrating the simplicity and convenience of the automated products and services. The rings expand from the pill like ripples on the water and symbolize change and transformation. The technological elements are emphasized by node-like line endings.
 
The new logo is complemented by a clean and modern typography, which harmoniously enhances the simplicity and style of the design.
 
In connection with iZafe receiving great interest internationally, the website is being launched in both Swedish and English and is designed to give visitors a deeper insight into the company's innovative work and commitment to patient safety and medical adherence.
 
"With the new logo and design, we are taking a powerful step into the future. We are strengthening our commitment to being the leading player in digital services for correct medication. This change reflects our determination to streamline our focus and corporate profile towards our core business. We are ready to shape a new era where we become the natural partner for healthcare companies globally, and our goal is clear – to help people stay healthy and live longer in their own homes.” says Anders Segerström, CEO iZafe Group.

Today, the Chairman of iZafe Group, Björn Rosengren, has acquired 500,000 Class B shares in the company, valued at 110,000 SEK (0.22 SEK per share.

In addition to today's transaction, Björn Rosengren also acquired 50,000 A-shares last week. Björn Rosengren now holds a total of 2,960,319 B-shares and 50,000 A-shares.

"I am pleased to increase my ownership in iZafe Group, which reflects my belief in the company's vision and potential," says Björn Rosengren. "These acquisitions demonstrate my continued commitment to supporting iZafe Group's strategic goals and creating value for its shareholders."

iZafe Group AB ("iZafe Group") announces today that the company has successfully completed all necessary technical integrations and adaptations to launch its groundbreaking medication robot, Dosell, in the Dutch market. These adaptations have included both technical adjustments in the Dosell device and platform, as well as extensive developments and customizations from our partner.

As a significant step forward, iZafe Group will now deliver 50 Dosell units to test the new customer journey in practice for one month. This phase of the pilot program will contribute to ensuring a smooth launch and customer experience. Following successful testing, the remaining 1,000 units will be delivered gradually throughout the rest of the year, according to the previously communicated plan.

"We are delighted to be part of this collaboration with iZafe Group for the launch of Dosell in the Dutch market. Dosell offers a groundbreaking digital medication robot that complements our existing portfolio of connected healthcare services. We are confident that Dosell will provide a reliable and secure alternative for the medication needs of our healthcare and alarm center clients in the Netherlands. Together, we can fulfill our shared mission of promoting independence and security in the simplest, safest, and most cost-effective way," says Martijn Van Bree, CEO of IVE Ventures.

"We are very pleased to have completed the technical integrations and adaptations for the launch of Dosell in the Dutch market. This marks a significant milestone for us and opens doors to a market known for its commitment to medication in pouches. The selection of Dosell by IVE Ventures after careful evaluation of competitors confirms the great potential of our product on the international stage. We look forward to collaborating with IVE and enabling a safe and efficient medication experience for their clients," says Anders Segerström, CEO of iZafe Group AB.

iZafe Group AB ("iZafe Group") announces today that they are now removing exclusive sales of Dosell via Apoteket.se and are instead opening up to future sales via several sales channels. This after receiving great international impact for their pharmaceutical robot and now having volume commitments from several countries, including the UK, Holland, Portugal and Spain.

iZafe has also started dialogues with several pharmacies regarding selling Dosell as a consumer product and will therefore initially sell Dosell on its own website Dosell.se, before it is gradually sold via more partners. The introductory offer on the hardware remains SEK 499 until the last of May, before the price is raised to SEK 1,999. The monthly fee of SEK 299 will be maintained.

"The launch of the consumer version has been a determining factor in being able to sign the partners we have now started this year with. We are very happy about the great international interest for Dosell and look forward to opening up more sales channels. Our goal is to make Dosell available to as many people as possible who need help managing their medication." says Anders Segerström, CEO of iZafe Group.

For more information about Dosell, visit Dosell.se.

iZafe Group AB ("iZafe Group") is pleased to announce that it has signed a collaboration agreement with Ti-Medi for the rights to sell and market the medication robot Dosell. Ti-Medi's minimum commitment over a four-year period is worth minimum SEK 12 million.

The first phase of the collaboration will start in October 2023, with the aim of ensuring the entire sales process and launching a unique concept from January 2024. The commitment is to sell at least 1,800 Dosell devices over four years. The revenue will gradually increase from the license revenue generated in connection with the launch in January 2024.
 
Ti-Medi is a global company that manufactures and distributes technical solutions for medication management compliance. Ti-Medi sells dose packaging machines to over 650 pharmacies in Spain and Portugal.
 
"We are pleased to welcome Ti-Medi as both a major shareholder and now also as a partner. Their broad experience in the pharmaceutical industry and their strong presence in the market make them an ideal partner to expand our sales of Dosell," says Anders Segerström, CEO of iZafe Group.
 
Over the last ten years, Ti-Medi has delivered technological solutions to healthcare professionals to make the management of Multi-Dosage Systems easier, safer, and more efficient. Currently, the company aims to offer technological solutions to patients as well.
 
"One in every two patients does not take their medication properly! We are pharmacists, and we truly believe in the role of the community pharmacy as a key player in the medication compliance challenge we are currently facing. With this partnership with Dosell, we aim to extend our value proposition to the end-patient, improving their quality of life by making it easier to manage their medication," says Marc Tarruell, Co-Founder of Ti-Medi.
 
For more information, please visit Ti-Medi's website, www.ti-medi.com/en.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

iZafe Group AB ("iZafe Group") hereby announces that the company has signed a cooperation agreement with MDM Pulse for the right to sell and market the pharmaceutical robot Dosell in Portugal. MDM Pulse's minimum commitment over a five-year period amounts to SEK 12.2 million to subsequently generate a recurring license income of at least SEK 4.2 million annually.

"We are very happy to have started this collaboration with MDM Pulse and thereby reach a new market in Europe for our pioneering pharmaceutical robot, Dosell. This collaboration represents a great opportunity for iZafe Group to continue driving innovation in the healthcare sector, also internationally. We look forward to working together with MDM Pulse to meet the needs of patients and healthcare providers in the Portuguese market and strengthen our position as a leading innovator in the industry.” says Anders Segerström, CEO of iZafe Group

MDM Pulse – Healthcare Solutions is a Portuguese company founded in 2006 that distributes medical technology products. The company has more than 20 years of experience in the IVD and pharmaceutical sectors. MDM Pulse has received several awards from business partners for its innovative and entrepreneurial approach, and has also been recognized by some of the most prestigious public institutions.

"By increasing patient safety and improving treatment adherence, Dosell provides an innovative solution that meets the challenges of Portugal's growing elderly population and the resulting increase in pharmaceutical drug consumption. Launching in Q3 this year, we will focus on the B2C market, and then expand to B2B market. Our partnership with iZafe represents an important milestone in closing the healthcare gap and promoting healthcare in Portugal." says Paula Matos, founder and CEO of MDM Pulse

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

iZafe Group AB ("iZafe Group" or the “Company”) hereby announces that that the Spanish company Ti-Medi has acquired approximately five percent of the shares in the Company, which makes Ti-Medi one of iZafe Group's largest shareholders. Ti-Medi has in total acquired 12,529,309 shares at the price of SEK 0.29 per share through a block deal brokered by Mangold Fondkommission.

Ti-Medi is a global company active in the manufacturing and distribution of technical solutions for compliance in pharmaceutical management. Ti-Medi sells dose packaging machines to over 650 pharmacies in Spain and Portugal.
For more information, see Ti-Medi's website, www.ti-medi.com/en.

"Our assessment is that the demand for iZafe Group's products and services will increase in the markets where we operate. We have long been looking for a company that develops and offers its customers precisely these types of services. Therefore, we have decided to invest in iZafe Group and we also hope to be able to find a good collaboration in the future to bring iZafe's products and services into Ti-Medi's product range in order to be able to offer these to our customers," says Marc Tarruell Tibau, co-founder of Ti-Medi

"The company has now gained a new strong and long-term owner that contributes with expertise and a global network. We view this very positively and interpret the investment as proof that iZafe Group's product and operations have support among knowledgeable market colleagues. We look forward to sharing the knowledge that Ti-Medi possesses about distribution in Southern Europe and initiating discussions about a future collaboration", says Anders Segerström, CEO of iZafe Group AB

As part of the internationalization strategy, iZafe Group has entered into a collaboration with the fintech platform eucaps.com. This is to facilitate the dissemination of information and dialogue with existing shareholders and to be able to reach out to new investors outside Sweden's borders.

"Eucap's platform offers opportunities for us at iZafe Group to drive international interest in our share, while at the same time we can easily interact and keep our existing owners updated on our development," says Anders Segerström CEO of iZafe Group AB and continues: "The internationalization of our business has taken off and as a step in the process we want to offer better conditions for international investors to follow our company and our share, which hopefully means increased international attention and new investors."

Eucap's platform offers global transparency and market access for companies in the European small-cap segment, which means, among other things, that companies traded on the Swedish stock exchange First North become accessible to investors from all over Europe. Eucaps ensures that investors have full access to accurate information, reports, stock prices, ownership data, news, etc.

"We are happy that iZafe has chosen to grow with us. Our goal is to make the opportunities in the European small-cap market visible to investors from all over the world. At the same time, we want to prevent market manipulation and create better liquidity and pricing for these companies," says Henrik Wagenius, CEO and founder of Eucaps.

To follow iZafe Group AB in Eucaps go to the following link: https://eucaps.com/izafe-group

Webbdesign av Comlog Webbyrå Stockholm